U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission

On December 22, 2017, the U.S. Food and Drug Administration (FDA) updated the product label for nilotinib to include information for providers on how to discontinue this drug in certain patients. With the updated dosing recommendations, select patients with chronic phase myeloid leukemia (CML) takin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Pulte, E. Dianne, Wroblewski, Tanya, Bloomquist, Erik, Tang, Shenghui, Farrell, Ann, Deisseroth, Albert, McKee, Amy E., Pazdur, Richard
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2019
Soggetti:
Regulatory Issues: FDA
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516133/
https://ncbi.nlm.nih.gov/pubmed/31019020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0759
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi